TNF and inflammatory bowel disease: Other double-blinded randomized controlled trials involving anti-TNF agents also demonstrated non-inferiority between remaining on an originator and switching to a biosimilar.13 Data accumulated from real-life cohorts on clinical efficacy, safety and immunogenicity of biosimilars likewise show comparable outcomes with the originator infliximab in both, anti-TNF-naïve and switched patients.14, , , –18 Switching from originator infliximab on a biosimilar due to economic reasons is now part of routine care in the treatment of IBD.